Department of Anaesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, USA.
Eur Rev Med Pharmacol Sci. 2022 Mar;26(6):2201-2214. doi: 10.26355/eurrev_202203_28369.
Disruption of intracellular Ca2+ homeostasis plays an important role as an upstream pathology in Alzheimer's disease (AD), and correction of Ca2+ dysregulation has been increasingly proposed as a target of future effective disease-modified drugs for treating AD. Calcium dysregulation is also an upstream pathology for the COVID-19 virus SARS-CoV-2 infection and replication, leading to host cell damage. Clinically available drugs that can inhibit the disturbed intracellular Ca2+ homeostasis have been repurposed to treat COVID-19 patients. This narrative review aims at exploring the underlying mechanism by which lithium, a first line drug for the treatment of bipolar disorder, inhibits Ca2+ dysregulation and associated downstream pathology in both AD and COVID-19. It is suggested that lithium can be repurposed to treat AD patients, especially those afflicted with COVID-19.
细胞内钙离子稳态的破坏在阿尔茨海默病(AD)中起着重要的上游病理作用,钙稳态的调节失常已被越来越多地提出作为治疗 AD 的未来有效疾病修饰药物的靶点。钙稳态失调也是 COVID-19 病毒 SARS-CoV-2 感染和复制的上游病理,导致宿主细胞损伤。临床上可用的抑制细胞内钙离子稳态紊乱的药物已被重新用于治疗 COVID-19 患者。本叙述性综述旨在探讨双相情感障碍一线治疗药物锂抑制 AD 和 COVID-19 中钙失调及相关下游病理的潜在机制。有研究表明,锂可以被重新用于治疗 AD 患者,特别是感染 COVID-19 的 AD 患者。